Cell Information:
Human Fibroblast-like synoviocytes (HFLS) represent a specialised cell type located inside joints in the synovium. HFLS are long known for their role in joint destruction by producing cytokines and metalloproteinases that contribute to cartilage degradation. Proinflammatory cytokines induce the proliferation, collagenase and aggrecanase production and GM-CSF secretion on HFLS. Ongoing arthritis research also has shown that HFLS express apoptosis and P53 mutations
Human Fibroblast-Like Synoviocytes (HFLS) are usually isolated from normal synovial tissues. These cells can be used as a good in vitro model for studyingthe pathogenesis of chronic inflammatory diseases, such as rheumatoid arthritis.
The Transfection Reagent:
Transfection of primary cells, such as HFLS, has always been challenging, both technically and financially. The most common systems currently used for molecular delivery to these cells include expensive electroporation instruments and relatively toxic chemical formulations.
Human Fibroblast-Like Synoviocyte (HFLS, HFLS-OA, HFLS-RA) Avalanche™ Transfection Reagent is a new, proprietary solution specifically designed for transfection on HFLS. The proprietary formulation oflipids and polymers ensures the highest possible transfection efficiencies and viabilities for HFLS. No other transfection reagents can match the efficiency, convenience, and gentleness of Human Fibroblast-Like Synoviocyte (HFLS, HFLS-OA, HFLS-RA) Avalanche™ Transfection Reagent for transfection on HFLS. For details of the developing process of this reagent, please go to: How did EZ Biosystems develop Avalanche™ Cell type/cell line specific transfection reagent series?
Features:
- Highest efficiency to ensure experimental success
- Extremely gentle to cells
- 0.5 ml is able to transfect about 1000 wells of 24-well plate
- Deliver single or multiple plasmids
- Compatible with transfection in any plate formats
- Reproducible: due to highly controlled chemical synthesis of each of the ingredients, the reagent forms uniformly sized complex particles with nucleic acids. With optimized protocol, our reagent will ensure the reproducible highest transfection results.
- Economical: High efficiency means less amount of nucleic acid & reagent is needed
- Developed and manufactured by EZ Biosystems
EZBiosystems美国EZBiosystems™公司是一家全球性转染试剂和基因表达生产服务提供商，公司的研发宗旨是让生命科学研究变得更简单，快速，容易！该公司主要产品之一为新一代转染试剂Avalanche 系列产品，该产品集合了组合化学，分子生物学和细胞生物学技术。公司致力于开发针对不同细胞类型的专用转染试剂。公司研发团队由多个学科经验丰富的专家组成，包括组合化学、脂类化学、生物物理学、分子生物学和细胞生物学。目前,EZBiosystems™主要提供广谱性基因及siRNA体外转染试剂、体内转染试剂、生物治疗性蛋白表达专用转染试剂以及150余种细胞特异性转染试剂。
EZBiosystems特约代理EZBiosystems品牌名称：EZBiosystemsEZBiosystems品牌logo：EZBiosystems品牌官网：http://ezbiosystems.com/EZBiosystems品牌链接：http://www.annoron.com/brand-342.htmlEZBiosystems品牌介绍：EZ生物系统™是一家全球性的基因转染和基因表达产品和服务提供商。EZBiosystems™isaworldwideprovideroftransfectionandgeneexpressionproducts&services.OneofthemajorfocusesofEZBiosystems™hasbeentheresearch,development,andmanufactureofnext-generationtransfectionreagents----theAvalanche®TransfectionReagentseriesbyapplyingourexpertiseincombinatorialchemistry,molecularBIOLOGy,andcellbiology. EZBiosystems品牌相关产品：品牌货号名称规格EZ BiosystemsEZT-CRPR-1Avalanche®-CRISPR Transfection Reagent0.5ml 1.5mlEZ BiosystemsEZT-OMNI-1Avalanche®-Omni Transfection Reagent0.75ml 1.5ml5*1.5mlEZ BiosystemsEZT-EVDY-1Avalanche®-Everyday Transfection Reagent0.75ml 1.5ml
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
鼠抗人CD3单克隆抗体针对人的CD3
CD3单克隆抗体，要看其说明书，该抗体是否识别其他生物（如大鼠）的CD3.
本试验阳性结果主要见于下列几种情况：
1.自身免疫性贫血，（IgG）型引起的溶血性贫血，本试验直接反应常呈强阳性，间接反应大多阴性，但亦可阳性。
2.药物诱发的免疫性溶血性贫血①α-甲基多巴型：直接及间接反应均阳性。②青霉素型：直接反应阳性，间接反应阴性，以上二型如以正常红细胞先与有关药物于37℃培育后再加病人血清、间接反应均为阳性。③福阿亭型：（奎宁等药物）抗体通常为IgM，偶有IgG型者，直接反应为阳性，间接反应阴性，但如用IgG抗血清做试剂则结果大部分均为阴性，但如培育时加入新鲜正常人血清（供应补体）则结果为阳性。
3.冷凝集素综合征直接反应阳性，间接反应阴性（试验需在37℃下进行）由于本病红细胞膜附着的是补体C4和C3而不是IgG或IgM，如果用抗IgG或抗IgM抗血清做试验时，则结果阴性，如以抗补体的抗血清做试验则直接反应阳性。
4.新生儿同种免疫溶血病，因Rh血型不合所致溶血病，直接及间接反应均强阳性，持续数周、换血输血后数天内可变为阴性，由于“ABO”血型不合引起的溶血病，结果常为阴性或弱阳性。
5.红细胞血型不合引起的输血反应，ABO或Rh血型不合输血，供者的红细胞被受者的血型抗体致敏，在供者被致敏的红细胞完全破坏以前，直接反应阳性，Rh阴性者如过去不曾接受过Rh阳性者的血或曾妊娠胎儿为Rh阳性者，间接反应阳性，如无上述接触，第一次输血后（Rh阳性的血），数天之内间接反应也会变为阳性。
6.其它在传染性单核细胞增多症、SLE、恶性淋巴瘤、慢性淋巴细胞白血病、癌肿、铅中毒、结节性动脉周围炎、EVan氏综合征等，病人直接反应亦可阳性，阵发性寒冷性血红蛋白尿症患者中，急性发作后用抗补体血清做试验直接反应常为阳性。展开
